First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Kan Yonemori et al.|Clinical Cancer Research|2021Cited by 97